Compositions comprising carriers and transportable complexes

• US 20020136732A1
• Filed: 04/19/2001
• Published: 09/26/2002
• Est. Priority Date: 04/23/2000
• Status: Abandoned Application

• Current Assignee: AriZeke Pharmaceuticals, Inc.
• Original Assignee: AriZeke Pharmaceuticals, Inc.
• Inventors: Houston, L. L.
• Application Number:
  US09/839,746
• Publication Number:
  US 20020136732A1
• Time in Patent Office: Days
• US Class Current: 424/178.1
• CPC Class Codes: A61K 47/50 the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• CPC Class Codes: A61K 47/51 the non-active ingredient being a modifying agent

Abstract

The present invention is directed toward compositions comprising one or more transportable complexes and one or more carriers and methods of making and using the same.

Claims

1. A composition comprising a carrier and a transportable compound wherein the transportable compound is associated with at least one recognition element for a cell surface transport moiety, wherein the cell surface transport moiety is involved in the transport of molecules across a plasma membrane or through a cell.

2. A composition according to claim 1 wherein the association between the recognition element and the transportable compound is covalent.

3. A composition according to claim 1 wherein the association between the recognition element and the transportable compound is non-covalent.

7. A composition according to claim 1 or claim 4 further comprising at least one protease inhibitor.

8. The composition of claim 1 or claim 4 wherein said transportable compound is selected from the group consisting of a small molecule, a protein, a peptide, a polypeptide, a nucleic acid, a lipid, a carbohydrate, a fatty acid, a polysaccharide, and an antigen.

11. A composition according to claim 1 or claim 4 wherein the recognition element is a small molecule.

12. A composition according to claim 1 or claim 4 wherein the recognition element is a polypeptide.

13. A composition according to claim 1 or claim 4 wherein the recognition element is an antibody or an antibody fragment.

14. A composition according to claim 13 wherein the antibody is a single chain variable region antibody fragment.

15. A composition according to claim 13 wherein the antibody or antibody fragment is specific for an epitope located on a stalk portion of a polymeric immunoglobulin receptor.

16. A composition according to claim 13 wherein the antibody or antibody fragment is specific for an epitope located on a secretory component a polymeric immunoglobulin receptor.

17. A composition according to claim 1 or claim 4 wherein the recognition element is a ligand for a cell surface transport moiety, wherein the cell surface transport moiety is involved in the transport of molecules across a plasma membrane or through a cell.

18. The composition of claim 17, wherein the ligand is a naturally occurring ligand.

19. The composition of claim 17, wherein the ligand is a synthetic ligand.

20. The composition of claim 17, wherein the ligand is selected from the group consisting of a small molecule, a peptide, a protein, a nucleic acid and derivatives thereof.

21. A composition according to claim 1 or claim 4 wherein the cell surface transport moiety is a receptor involved in the transport of molecules across a plasma membrane or through a cell.

22. The composition of claim 21 wherein the receptor is selected from the group consisting of a transferrin receptor, a fibroblast growth receptor, a low density lipoprotein receptor and a polymeric immunoglobulin receptor.

23. A composition according to claim 21 wherein the cell surface transport moiety is a polymeric immunoglobulin receptor.

24. A composition according to claim 21 wherein the cell surface transport moiety is a secretory component of a polymeric immunoglobulin receptor.

25. A composition according to claim 21 wherein the cell surface transport moiety is a stalk of a polymeric immunoglobulin receptor.

26. A composition according to claim 1 or claim 4 wherein the cell is an epithelial cell.

27. A composition according to claim 26 wherein the cell surface transport moiety is presented on the luminal surface of the cell.

28. A composition according to claim 1 or claim 4 wherein the carrier is a pharmaceutically acceptable carrier.

29. A composition according to claim 1 or claim 4 that is a composition selected from the group consisting of a dry composition, a liquid composition and an aqueous composition.

30. A composition according to claim 1 or claim 4 that is a mucoadhesive formulation.

31. A composition according to claim 1 or claim 4 encapsulated in an enteric coating.

32. A composition according to claim 1 or claim 4 that is a sustained release formulation.

33. A method for delivering a transportable compound to a cell, the method comprising exposing a cell to a composition according to claim 1 or claim 4.

34. A method according to claim 33 wherein the exposing occurs in vitro.

35. A method according to claim 33 wherein the exposing occurs in vivo.

36. A method according to claim 33 wherein at least one of the transportable compound and the transportable complex of the composition is transported across a plasma membrane.

37. A method according to claim 33 wherein at least one of the transportable compound and the transportable complex of the composition is moved across the cell.

38. A method according to claim 33 wherein at least one of the transportable compound and the transportable complex of the composition is moved through the cell.

39. A method according to claim 33 wherein at least one of the transportable compound and the transportable complex of the composition is released from a cell at a different location than the location at which it is contacted to the cell.

40. A method according to claim 39 wherein one of said locations is the basolateral surface of an epithelial cell.

41. A method of making a composition according to claim 1 or claim 4 comprising combining a carrier with a transportable or a transportable complex.

42. A method according to claim 41 further comprising encapsulating the composition.

43. A method according to claim 42 further comprising coating the encapsulated composition.

44. A method according to claim 41 wherein the composition is selected from the group consisting of a dry composition, a liquid composition and an aqueous composition.

45. A method according to claim 41 wherein the composition is a sustained release formulation.

46. A method according to claim 41 wherein the composition is suitable for inhalation therapy.

4. A composition comprising a carrier and a transportable complex comprising at least one transportable compound, wherein the transportable complex is associated with a recognition element for a cell surface transport moiety, wherein the cell surface transport moiety is involved in the transport of molecules across a plasma membrane or through a cell.

5. A composition according to claim 4 wherein the association between the recognition element and the transportable complex is covalent.

6. A composition according to claim 4 wherein the association between the recognition element and the transportable complex is non-covalent.

9. The composition of claim 4 wherein the transportable complex is a liposome.

10. The composition of claim 4 wherein the transportable complex is a gene delivery vehicle.